Skip to main content

Table 3 All SymX and AsymX patients on the diet are summarized in Table 3

From: Outcomes of mitochondrial long chain fatty acid oxidation and carnitine defects from a single center metabolic genetics clinic

Groups

Patient#/study ID/diagnosis

Long chain fat intake

MCT

Protein Intake

(g/kg/d)

Recommended intake

Actual intake

Recommended intake

Actual intake

SymX group

6/6/CPTII def

20%

30%

NA

NA

1.09

7/14/CPTII def

20%

 < 20%

10–15%

1%

1.17

8/15/CPTII def

35%

44%

10–20%

10–20%

1.33

9/37/LCHAD def

10%

8%

10–15%

0%

NA

10/42/VLCAD def

10–15%

6%

10–15%

21%

2.12

11/52/VLCAD def

5%

5%

35%

35%

2.94

14/48/MAD def

25–30%

33%

NA

NA

2.32

AsymX group

24/38/LCHAD def

10%

7%

15–25%

23%

2.57

25/39/LCHAD def

10–15%

10%

20–25%

22%

2.13

26/53/LCHAD def

10%

10%

30%

32%

2.30

27/40/VCLAD def

15–25%

26%

5%

0%

0.97

28/43/VLCAD def

15–25%

13%

13%

13%

1.51

29/44/VLCAD def

10–20%

10–12%

15–20%

15%

2.15

  1. CACT carnitine acylcarnitine translocase; CPT-I carnitine palmitoyltransferase I; CPT-II carnitine palmitoyltransferase II; CTD carnitine transporter defect; def deficiency; LCHAD long-chain 3-hydroxyacyl-CoA dehydrogenase; MAD multiple acyl-CoA dehydrogenase; VLCAD very long-chain acyl-CoA dehydrogenase